AN2 Therapeutics (ANTX) financial statements
Net income was -$35M.
The diluted share count rose 1045% over the period (dilution).
Income statement
Fiscal years, from AN2 Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Research and development | $16M | $29M | $55M | $40M | $25M |
| Selling, general and admin | $5M | $13M | $15M | $14M | $13M |
| Operating income | -$22M | -$42M | -$70M | -$57M | -$38M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$22M | -$41M | -$65M | -$51M | -$35M |
| EPS (diluted) | -$10.64 | -$2.79 | -$2.74 | -$1.72 | -$1.16 |
| Diluted shares | 3M | 15M | 24M | 30M | 30M |
Balance sheet
Fiscal years, from AN2 Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and short-term investments | $59M | $99M | $107M | $84M | $58M |
| Total current assets | $60M | $99M | $111M | $86M | $60M |
| Total assets | $65M | $103M | $139M | $92M | $62M |
| Total current liabilities | $3M | $7M | $14M | $10M | $9M |
| Total liabilities | $3M | $7M | $14M | $10M | $9M |
| Shareholders' equity | -$47M | $95M | $125M | $82M | $53M |
| Net debt | -$12M | -$27M | -$16M | -$21M | -$20M |
Cash flow
Fiscal years, from AN2 Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$20M | -$33M | -$53M | -$49M | -$30M |
| Stock-based compensation | $974,000 | $4M | $8M | $8M | $6M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ANTX.
Open ANTX in InvestinglyFrom AN2 Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.